---
title: "UBS: Expects the healthcare sector's revenue to continue growing by 10% this year, downgrades 3SBIO to preferred choice"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277410631.md"
description: "UBS released a research report stating that based on the latest industry sales data and authorized transaction conditions, the median revenue growth forecast for the healthcare companies it rates is expected to be 16% and 10% for 2025 and 2026, respectively. It believes that the core product sales performance of most companies will meet or exceed its expectations. UBS has listed 3SBIO as its preferred stock, replacing Hansoh Pharmaceutical, and has given 3SBIO a \"Buy\" rating with a target price of HKD 41, considering its valuation reasonable. Looking ahead to 2026, the bank forecasts a median revenue growth of 10% for the sector, optimistic about the steady growth of innovative drug sales and favorable R&D progress. The bank has also raised the target prices for several stocks, increasing the target price for CSPC Pharmaceutical from HKD 10 to HKD 10.9, Hansoh Pharmaceutical from HKD 48.2 to HKD 51.5, and Heng Rui Medicine from HKD 96.9 to HKD 98.3, assigning \"Neutral,\" \"Buy,\" and \"Buy\" ratings, respectively"
datetime: "2026-03-02T06:02:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277410631.md)
  - [en](https://longbridge.com/en/news/277410631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277410631.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277410631.md) | [English](https://longbridge.com/en/news/277410631.md)


# UBS: Expects the healthcare sector's revenue to continue growing by 10% this year, downgrades 3SBIO to preferred choice

According to the latest industry sales data and authorized transaction situation, UBS has released a research report predicting that the median revenue growth for the healthcare companies it rates will be 16% and 10% for 2025 and 2026, respectively. It believes that the core product sales performance of most companies will meet or exceed its expectations.

UBS has listed 3SBIO (01530) as its preferred stock, replacing Hansoh Pharmaceutical (03692), and has given 3SBIO a "Buy" rating with a target price of HKD 41, considering its valuation reasonable. Looking ahead to 2026, the bank predicts a median revenue growth of 10% for the sector, optimistic about the steady growth of innovative drug sales and favorable R&D progress.

The bank has also raised the target prices for several stocks, increasing the target price for CSPC Pharmaceutical Group (01093) from HKD 10 to HKD 10.9, Hansoh Pharmaceutical's target price from HKD 48.2 to HKD 51.5, and Heng Rui Medicine (01276) target price from HKD 96.9 to HKD 98.3, giving "Neutral," "Buy," and "Buy" ratings, respectively

### 相關股票

- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-HK/quote/159570.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [3SBIO (01530.HK)](https://longbridge.com/zh-HK/quote/01530.HK.md)

## 相關資訊與研究

- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md)
- [Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$38 From HK$37.87, Keeps at Neutral](https://longbridge.com/zh-HK/news/281164648.md)
- [HSBC Starts Minimax Group at Hold With HK$1,000 Price Target](https://longbridge.com/zh-HK/news/281501067.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-HK/news/281035304.md)
- [3SBio Seeks HK$3.12 Billion via Share Sale](https://longbridge.com/zh-HK/news/268172267.md)